NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the completion of the Phase 1 study of VLS-01 in healthy participants. “We are pleased to report the completion of the Phase 1 study of VLS-01, in which we demonstrated a supportive PK/
